In a clinical study, Control-IQ technology significantly improved time in range.

In the National Institutes of Health-funded Diabetes Closed Loop Trial, Protocol 3, time in range* for participants using a t:slim X2™ insulin pump with Control-IQ™ technology for six months averaged 71% per day compared to 59% for sensor-augmented pump therapy alone.1

View clinical evidence

71%

Time in range* per day (24 hours) for study participants using Control-IQ technology on the t:slim X2 pump.1

76%

Overnight time in range (12 a.m.-6 a.m.)* for study participants using Control-IQ technology.1

For patients who aren’t hitting HbA1c targets, the t:slim X2 pump with Control-IQ technology can help.

A patient’s struggle with glucose control impacts loved ones, caregivers, and even coworkers. Our easy-to-use t:slim X2 insulin pump with Control-IQ technology helps patients achieve targets, and better glucose management means happier patients. Regardless of baseline A1c, most study participants had a reduction over the 6‑month pivotal trial.1

How does Control-IQ technology work?

Control-IQ technology helps increase time in range* using Dexcom G6 continuous glucose monitoring (CGM) values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly, including delivery of automatic correction boluses as needed.

Illustration of How Control-IQ Works

Smooth Basal Rate Attenuation

Control-IQ technology smoothly decreases or discontinues basal delivery based on falling CGM values to help prevent hypoglycemia.

Control-IQ Technology Decreasing Basal

Automatic Correction Boluses

Control-IQ technology gradually increases basal insulin with increasing CGM values and administers 60% correction boluses once an hour as needed to help prevent hyperglycemia.

Control-IQ Technology Auto Bolus

Sleep and Exercise Activity Settings

Control-IQ technology includes optional settings for Sleep and Exercise Activities that adjust treatment ranges to better match physiologic needs when active or sleeping.

Control-IQ Technology Sleep Activity

Control-IQ technology offers a variety of features designed to help make control easier for your patients.

Automatic Basal Insulin Adjustments

Control-IQ technology automatically adjusts insulin levels based on Dexcom G6 CGM readings. The system uses a predictive algorithm to minimize wide fluctuations in glucose levels, increasing time in range.* In studies, the system was available 92% of the time.1

Automatic Correction Boluses

Control-IQ technology can deliver automatic correction boluses, a first for automated insulin delivery devices.

High Usability Ratings From Patients

On a 5-point scale, with 5 representing the optimal score, study participants rated the Control-IQ system a 4.8 for desire to continue use of the system, 4.7 for ease of use, and 4.5 for trust.2

Improved HbA1c and Mean Glucose

For patients struggling with glucose control, using Control-IQ technology may be able to help more easily achieve their targets. Study participants using Control-IQ technology saw statistically significant improvements in HbA1c and mean glucose values.1

Decreased Hyperglycemia

Time spent with glucose values above 180 mg/dL was only 27% in those using the t:slim X2 insulin pump with Control-IQ technology compared to 39% in the control group.1

Zero Fingersticks

When the t:slim X2 pump is integrated with Dexcom G6 CGM, zero fingersticks are required for calibration or mealtime dosing.§

 
 
§ Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Responsible Use of Control-IQ Technology

Even with advanced systems such as the t:slim X2 insulin pump with Control-IQ technology, patients are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that patients accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Since there are situations and emergencies that the system may not be capable of identifying or addressing, patients should always pay attention to their symptoms and treat accordingly.

* As measured by CGM.
† CGM sold separately.
‡ If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus with a target of 110 mg/dL and delivers 60% of that value. It will do this up to once per hour as needed.
§ Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

References:
1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17. DOI: 10.1056/NEJMoa1907863
2. Brown S, et al. Clinical Acceptance of the Artificial Pancreas: The iDCL Trial. Poster presentation. 79th Scientific Sessions, American Diabetes Association, San Francisco, CA; June 9, 2019.

Important Safety Information

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and Control-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with integrated technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

 
Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and Control-IQ technology must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.